Sun purges 18 Ranbaxy execs in integration move

Weeks after Sun Pharmaceutical completed its acquisition of troubled Ranbaxy Laboratories, 18 top execs have reportedly been given their pink slips. The Economic Times reports that executives let go include President and CFO Indrajit Banerjee and Yugal Sikri, who headed operations in India. A source said another 150 executives would be terminated as the company continues its integration. Sun has said its top priority is to restore the rights of four Ranbaxy plants now banned by the FDA to ship products to the U.S. Story | More

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.